{
  "guid": "0ca20793-ec01-4bf7-b3af-ed6ea2b2790c",
  "title": "Man, Mosquito, Malaria Vaccine",
  "description": "<p>Playing out against the backdrop of a global pandemic (including recent massive surges in regions around the world) is the <a href=\"https://www.ox.ac.uk/news/2021-04-23-malaria-vaccine-becomes-first-achieve-who-specified-75-efficacy-goal\" target=\"_blank\">news that came out</a> a week ago that a candidate \"malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal”. While the findings are still in <a href=\"https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3830681\" target=\"_blank\">preprint</a> with <i>The Lancet</i>, the resulting buzz and phrases quoted included everything from “unprecedented”, “groundbreaking work”, and “very exciting” to “high expectations”, “highly effective”, and “a hugely significant extra weapon”... A \"weapon\" in the war against malaria that is -- a disease that is estimated to cause over 400,000 deaths each year globally, and predominantly in children under the age of five.</p><p>So in this special 2x explainer episode of 16 Minutes (also running on the a16z Podcast), we -- <a href=\"https://www.takeda.com/who-we-are/company-information/executive-leadership/rajeev-venkayya/\" target=\"_blank\">Rajeev Venkayya</a> of Takeda Pharmaceuticals, a16z bio general partner Jorge Conde, and Sonal Chokshi -- dig into what's hype/ what's real about this news, beyond the headlines and beyond the buzz. What does the data tell us, what does the current study phase mean, and <a href=\"https://www.nature.com/articles/d41586-021-01096-7\" target=\"_blank\">what's left</a> to get to widespread, real-world use? How does this candidate vaccine (R21 from Jenner Institute/ Oxford University) compare to the other malaria vaccine (RTS,S from GlaxoSmithKline)? How do, and don't, advances in and around COVID vaccines play here? And why has it been so hard to develop vaccines for this particular disease?</p><p>Because we also cover (as is the premise of the show) where we are on the long arc of innovation... and this is an innovation story that's been <a href=\"https://academic.oup.com/cid/article/60/6/930/497479\" target=\"_blank\">nearly a century</a> in the making. </p>\n",
  "pubDate": "Sun, 2 May 2021 01:36:33 +0000",
  "author": "content+a16zpodcast@a16z.com (Jorge Conde, Sonal Chokshi, Rajeev Venkayya)",
  "link": "https://a16z.simplecast.com/episodes/malaria-vaccine-breakthrough-science-tech-innovation-kfCQT8_a",
  "content:encoded": "<p>Playing out against the backdrop of a global pandemic (including recent massive surges in regions around the world) is the <a href=\"https://www.ox.ac.uk/news/2021-04-23-malaria-vaccine-becomes-first-achieve-who-specified-75-efficacy-goal\" target=\"_blank\">news that came out</a> a week ago that a candidate \"malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal”. While the findings are still in <a href=\"https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3830681\" target=\"_blank\">preprint</a> with <i>The Lancet</i>, the resulting buzz and phrases quoted included everything from “unprecedented”, “groundbreaking work”, and “very exciting” to “high expectations”, “highly effective”, and “a hugely significant extra weapon”... A \"weapon\" in the war against malaria that is -- a disease that is estimated to cause over 400,000 deaths each year globally, and predominantly in children under the age of five.</p><p>So in this special 2x explainer episode of 16 Minutes (also running on the a16z Podcast), we -- <a href=\"https://www.takeda.com/who-we-are/company-information/executive-leadership/rajeev-venkayya/\" target=\"_blank\">Rajeev Venkayya</a> of Takeda Pharmaceuticals, a16z bio general partner Jorge Conde, and Sonal Chokshi -- dig into what's hype/ what's real about this news, beyond the headlines and beyond the buzz. What does the data tell us, what does the current study phase mean, and <a href=\"https://www.nature.com/articles/d41586-021-01096-7\" target=\"_blank\">what's left</a> to get to widespread, real-world use? How does this candidate vaccine (R21 from Jenner Institute/ Oxford University) compare to the other malaria vaccine (RTS,S from GlaxoSmithKline)? How do, and don't, advances in and around COVID vaccines play here? And why has it been so hard to develop vaccines for this particular disease?</p><p>Because we also cover (as is the premise of the show) where we are on the long arc of innovation... and this is an innovation story that's been <a href=\"https://academic.oup.com/cid/article/60/6/930/497479\" target=\"_blank\">nearly a century</a> in the making. </p>\n",
  "enclosure": "",
  "itunes:title": "Man, Mosquito, Malaria Vaccine",
  "itunes:author": "Jorge Conde, Sonal Chokshi, Rajeev Venkayya",
  "itunes:duration": "00:36:20",
  "itunes:summary": "with @jorgecondebio @rvenkayya @smc90\n\nWe dig into what's hype/ what's real about news of a breakthrough malaria vaccine candidate, beyond the headlines and beyond the buzz: data, science, tech, and the long arc of innovation. Because this is an innovation story that's been nearly a century in the making, yet also playing out amongst a global pandemic.",
  "itunes:subtitle": "with @jorgecondebio @rvenkayya @smc90\n\nWe dig into what's hype/ what's real about news of a breakthrough malaria vaccine candidate, beyond the headlines and beyond the buzz: data, science, tech, and the long arc of innovation. Because this is an innovation story that's been nearly a century in the making, yet also playing out amongst a global pandemic.",
  "itunes:keywords": "vaccines, science, malaria, innovation, covid, biology",
  "itunes:explicit": "no",
  "itunes:episodeType": "full",
  "itunes:episode": 634
}